|  |
|
|
| |
Symposium lectures on-line
20 February, 2009
Most of the lectures of the Symposium were published on-line. You can find the video presentations at the top of each lecture abstract. We hope to complete the whole on-line program in the near feature.
Pictures of Semmelweis Symposium 2008
1 January, 2009
You can find the pictures of all the three days of Semmelweis Symposium 2008 here. Lecture of Prof. Sándor Kovács
31 December, 2008
You can find the whole video-presentation of Prof. Sándor Kovács at " Lectures" on the following page.
Summary
30 November, 2008
More than 500 participants from 20 countries attended Semmelweis Symposium 2008. You can find a detailed summary of the event here. A summary of press echo in the Hungarian media you can find here.
Poster abstracts
27 November, 2008
You can find the poster abstracts of Semmelweis Symposium 2008 here.
Scientific Program - printable version
23 November, 2008
You can download the printable version of the Scientific Program here.
Cardiovascular pharmacogenomics course
22 November, 2008
According to the program of Semmelweis Symposium, Peter Pokreisz (Katholieke Universiteit Leuven, Belgium) will give a lecture (in Hungarian) on cGMP regulatory mechanisms in cardiology at 18:00 Wednesday, 26 November.
Abstract submission period extended
14 November 2008
The deadline for abstract submission was extended until 18 November 2008. More detailes on the Abstract submission form.
On-line registration
4 November. 2008
Participation in the program of Semmelweis Symposium 2008 is free. However, completion the on-line registration form is required to attend the Symposium. Abstract submission for poster presentation
3 November, 2008
Abstracts for poster presentation are welcome to the Semmelweis Symposium. Deadline for abstract submission is 15 November. More detailes on the Abstract Submission Form.
PhD course registration
2 November, 2008
Semmelweis Symposium 2008 was accredited by the School of Doctoral Studies of Semmelweis University. Students attending all the three days of the Symposium will get 2 PhD credits.
OFTEX registration
2 November, 2008
Semmelweis Symposium 2008 was registred to the OFTEX system. Colleagues attending all the three days of the Symposium will get 20 OFTEX credits. For detailed information look for SE-TK/2008-07/00383 at www.oftex.hu .
Final program
30 October, 2008
The final program of the Symposium has been completed. For detailes visit to the Scientific Program pages.
Current trends in Cardiology
18 August. 2008
This year cardiology is in the focus of Semmelweis Symposium. The members of the Heart Center take the opportunity to kindly invite you to this event.
|
|
|
|
 |
Prolactin-releasing peptide regulates cardiac contractility
- Gábor, Füredi; Attila, Kónyi; Réka, Skoumal; Ábel, Perjés; Miklós, Tóth; Heikki, Ruskoaho; István, Szokodi
- Heart Institute, Medical School, University of Pécs;
Department of Pharmacology and Toxicology, Faculty of Medicine, University of Oulu;
Department of Health Sciences and Sport Medicine, Faculty of Physical Education and Sport Sciences, Semmelweis University
Purpose - The hypothalamic prolactin-releasing peptide (PrRP), which is the endogenous ligand of the orphan receptor GPR10, plays an important role in the regulation of the central stress response, sleep regulation and feeding behavior. Although specific binding sites have been found in the rat myocardium, the functional importance of PrRP in the regulation of cardiovascular system is still unknown. The objective of the present study was to characterize the direct cardiac effects of PrRP as well as the underlying signaling mechanisms. Methods and Results - In the isolated perfused, paced rat heart preparation (male 7-week-old, Sprague-Dawley rats, n="138"), intracoronary infusion of PrRP-31 (1-30 nmol/L) for 15 min induced a dose-dependent, slowly developing positive inotropic effect, with a maximal increase in developed tension at the dose of 10 nmol/L (13.6%±3.1, P< 0.001). Next we tested if various counter-regulatory mechanisms could modify the effect of PrRP. The phosphodiesterase inhibitor IBMX (10 µmol/L) failed to alter the inotropic response to PrRP (10.7±1.9%, P=N.S.) excluding the involvement of cAMP-dependent mechanisms. In contrast, the specific protein kinase C-alfa (PKC-alpha) inhibitor Ro32-0432 (100 nmol/L) significantly increased the inotropic response to PrRP (21.6±3.4%, P<0.05) as well as the phosphorylation of phospholamban at Ser-16 (1.5±0.09 vs. 1.0±0.18; P<0.001) as measured by Western blotting. Moreover, the protein phosphatase (PP1/PP2A) inhibitor calyculin A (CyA) augmented the effect of PrRP on contractility (20.7 ±1.7%, P<0.001) similarly to PKC-alpha inhibition, whereas the PP2A inhibitor okadaic acid (10 nmol/L) had no effect (7.8±1.0 %, P=N.S.). Furthermore, long-term (120 min) administration of PrRP resulted in a greater increase in contractility (20.3±3.1 %) as compared to short-term infusion (15 min; P<0.05). Conclusions - Our results provide the first evidence for the functional significance of PrRP in the heart. The positive inotropic effect of PrRP is mediated via cAMP-independent mechanisms, which are suppressed by enhanced activity of PKC-alpha and PP1. We suggest that PrRP may play an important role in the long-term regulation of myocardial contractility.
|
|
